Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Phase 2 Completed
41 enrolled 10 charts
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
Phase 2 Terminated
11 enrolled 6 charts
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 2 Completed
43 enrolled
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Phase 2 Completed
21 enrolled 9 charts
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
80 enrolled
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
54 enrolled
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Terminated
45 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Phase 1 Completed
Geldanamycin Analogue in Treating Patients With Advanced Cancer
Phase 1 Completed
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
78 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 1 Terminated
30 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
48 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Tanespimycin in Treating Patients With Stage III-IV Melanoma
Phase 2 Terminated
50 enrolled
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Phase 1 Completed
50 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase 1 Completed
35 enrolled
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Phase 2 Completed
9 enrolled 8 charts
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Phase 2 Completed
37 enrolled